Over 20 Different Brands Of Ice Cream Recalled For Potential Plastic Contamination
Wells Enterprises, an Iowa-based ice cream manufacturer, which is the parent company of Blue Bunny, Bomb Pops, and Halo Top, issued the voluntary recall last month, according to recently released information from the Food and Drug Administration.
Dallas news outlet KXAS-TV reports that the nationwide recall includes 22 flavors across a variety of brands of ice cream and frozen yogurt, which were all sold in three-gallon containers. The ice cream was distributed from 103 centers across the United States, including Houston, Texas and Fort Worth, Texas.
The recalled products have 'Best If Used By' dates ranging from March to October 2026. If you picked up any of these flavors before the long weekend and the summer heatwaves, throw them out or return to the store where they were purchased.
These are the affected products. More details, including recall numbers, codes, quantities and descriptions, were posted online by the FDA:
Rocky Road Flavored Ice Cream: 169 3-gallon tubs
Mocha Almond Fudge Ice Cream: 359 3-gallon tubs
Peanut Butter N' Fudge Ice Cream: 201 3-gallon tubs
Country Rich Vanilla Ice Cream: 240 3-gallon tubs
Scooper Hero Ice Cream: 726 3-gallon tubs
Cotton Candy Flavored Ice Cream: 39 3-gallon tubs
GFGB Vanilla Bean Flavored Ice Cream: 120 3-gallon tubs
Quick Blend Vanilla Flavored Ice Cream: 280 3-gallon tubs
Planet Smoothie ZSA Vanilla Flavored Fat Free Frozen Yogurt: 937 3-gallon tubs
Johnny Rockets Vanilla Flavored Ice Cream: 100 3-gallon tubs
BIPC Flavored Ice Cream: 1,858 3-gallon tubs
Vanilla Frozen Yogurt: 5,280 3-gallon tubs
Vanilla Flavored Ice Cream: 961 3-gallon tubs
GFGB 12% Vanilla Flavored Ice Cream: 109 3-gallon tubs
Gordon Choice Vanilla Flavored Ice Cream: 1,080 3-gallon tubs
Vanilla Bean Ice Cream with Madagascar vanilla: 320 3-gallon tubs
Glenview Farms Vanilla Flavored Ice Cream: 1,573 3-gallon tubs
Glenview Farms Chocolate Ice Cream: 67 3-gallon tubs
Glenview Farms Artificially Flavored French Vanilla Ice Cream: 2,261 3-gallon tubs
Artificially Flavored French Vanilla Ice Cream: 17 3-gallon tubs
Keith Valley Vanilla Flavored Ice Cream: 569 3-gallon tubs
Ellington Farms Vanilla Flavored Ice Cream: 600 3-gallon tubs
In case you're still hankering for ice cream, here's our recipe for a homemade treat.
Read the original article on Southern Living
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
an hour ago
- Boston Globe
US health officials crack down on kratom-related products after complaints from supplement industry
The FDA action 'is not focused on natural kratom leaf products,' according to a statement Tuesday by the U.S. Department of Health and Human Services. Advertisement The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up '7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A federal ban wouldn't take effect until the agency drafts and finalizes new rules governing the ingredient. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Advertisement Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety. Supplement executives quickly applauded the move. The FDA 'demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements Nearly a decade ago, the federal government came close to banning the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1, reserved for drugs that have no medial use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders. Advertisement In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine
2 hours ago
US health officials crack down on kratom-related products after complaints from supplement industry
WASHINGTON -- U.S. health officials are warning Americans about the risks of an opioid-related ingredient increasingly added to energy drinks, gummies and supplements sold at gas stations and convenience stores, recommending a nationwide ban. The chemical, known as 7- hydroxymitragynine, is a component of kratom, a plant native to Southeast Asia that has gained popularity in the U.S. as an unapproved treatment for pain, anxiety and drug dependence. In recent months, dietary supplement companies that sell kratom have been urging the Food and Drug Administration to crack down on the products containing 7-OH, portraying it as a dangerously concentrated, synthetic form of the original ingredient. The FDA action 'is not focused on natural kratom leaf products," according to a statement Tuesday by the U.S. Department of Health and Human Services. The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin. '7-OH is an opioid that can be more potent than morphine," said FDA Commissioner Marty Makary. "We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A federal ban wouldn't take effect until the agency drafts and finalizes new rules governing the ingredient. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety. Supplement executives quickly applauded the move. The FDA "demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements Nearly a decade ago, the federal government came close to banning the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1, reserved for drugs that have no medial use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders. In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine. Sometimes referred to collectively as 'gas station heroin,' the drugs have been restricted by several states, but they are not scheduled at the federal level. ___
Yahoo
2 hours ago
- Yahoo
AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio
